Back to News
Market Impact: 0.1
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Source: globenewswire.com
Healthcare & BiotechTechnology & Innovation
The text describes an unnamed company as a recognized leader in RNAi drug discovery, citing its track record advancing delivery platforms and therapeutics. It highlights the company's integrin-mediated delivery platform but provides no specific results, figures, or new development.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- ‘I don’t care how it’s done’: Trump pressures Ukraine to cut peace deal
- Super Micro’s stock soars after surprise update — with Dell and HPE shares joining the rally
- Australian AI data centre operator NextDC shares shed 44% on revenue delay
- SpaceX posts first operating profit as public company as AI revenue nearly triples to $7.6 billion—cruising past Starlink
- SpaceX says big AI growth fueled revenue jump
- A top medical technology stock is trading at a big discount. Here's why I'm buying